1. Home
  2. MDGL vs ONTO Comparison

MDGL vs ONTO Comparison

Compare MDGL & ONTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • ONTO
  • Stock Information
  • Founded
  • MDGL 2011
  • ONTO 1940
  • Country
  • MDGL United States
  • ONTO United States
  • Employees
  • MDGL N/A
  • ONTO N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • ONTO Industrial Machinery/Components
  • Sector
  • MDGL Health Care
  • ONTO Industrials
  • Exchange
  • MDGL Nasdaq
  • ONTO Nasdaq
  • Market Cap
  • MDGL 6.8B
  • ONTO 6.1B
  • IPO Year
  • MDGL N/A
  • ONTO N/A
  • Fundamental
  • Price
  • MDGL $290.96
  • ONTO $99.35
  • Analyst Decision
  • MDGL Strong Buy
  • ONTO Strong Buy
  • Analyst Count
  • MDGL 10
  • ONTO 9
  • Target Price
  • MDGL $420.63
  • ONTO $186.25
  • AVG Volume (30 Days)
  • MDGL 361.7K
  • ONTO 1.8M
  • Earning Date
  • MDGL 05-01-2025
  • ONTO 05-08-2025
  • Dividend Yield
  • MDGL N/A
  • ONTO N/A
  • EPS Growth
  • MDGL N/A
  • ONTO 57.20
  • EPS
  • MDGL N/A
  • ONTO 4.42
  • Revenue
  • MDGL $317,383,000.00
  • ONTO $1,025,082,000.00
  • Revenue This Year
  • MDGL $264.55
  • ONTO $6.65
  • Revenue Next Year
  • MDGL $67.21
  • ONTO $10.35
  • P/E Ratio
  • MDGL N/A
  • ONTO $22.48
  • Revenue Growth
  • MDGL N/A
  • ONTO 21.23
  • 52 Week Low
  • MDGL $200.08
  • ONTO $98.21
  • 52 Week High
  • MDGL $377.46
  • ONTO $238.93
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 40.85
  • ONTO 39.41
  • Support Level
  • MDGL $280.00
  • ONTO $85.88
  • Resistance Level
  • MDGL $307.54
  • ONTO $104.27
  • Average True Range (ATR)
  • MDGL 15.97
  • ONTO 5.52
  • MACD
  • MDGL -2.00
  • ONTO -1.89
  • Stochastic Oscillator
  • MDGL 15.88
  • ONTO 30.36

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About ONTO Onto Innovation Inc.

Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.

Share on Social Networks: